Journal rankings · indicator year 2025
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2025
Hematology journal rankings 2025
78 ranked journals · Subfield in Medicine
Hematology has 78 ranked journals in 2025. The median OJR rose 0.07 on 2024 to 0.66, below the world average of 1.00; Q1 starts at OJR 1.04. The highest-scoring journal with a stable rank is The Lancet Haematology: its likely rank is within the top 3.
Ranks and citation indicators: 2025. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2022–2024, the window the 2025 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Hematology78
Show all 42 subfields
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
78 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. The small range under it is the likely rank range: in 95% of 1,000 resamples of the journal’s papers, it ranked inside that range. Journals whose ranges overlap are not clearly different. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2024. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2022–2024, the window the 2025 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2022–2024 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2016 to 2025. A label compares the 2022→2025 change with the median change of the journal’s field or domain. Rising needs a relative change of +10% or more that is at least 2 standard errors above zero; Falling needs -9.1% or less (rounded), at least 2 standard errors below zero. Sorting uses that relative change. | Compare |
|---|---|---|---|---|---|---|---|
Rank 1; likely between #1 and #2 of 78The Lancet HaematologyElsevier BV · Netherlands | 3.72Q1 | 11.26 1.38 up from 2024 | 399 | 31% | $7,280 | ||
Rank 2; likely between #1 and #6 of 78LeukemiaSpringer Nature · United Kingdom | 2.92Q1 | 6.35 3.82 down from 2024 | 932 | 73% | $5,190 | ||
Rank 3; likely between #2 and #5 of 78BloodElsevier BV · United States | 2.70Q1 | 7.49 1.24 down from 2024 | 2,137 | 64% | $5,500 | ||
Rank 4; likely between #2 and #5 of 78Blood Cancer JournalOASpringer Nature · United Kingdom | 2.57Q1 | 7.81 0.58 up from 2024 | 568 | 100% | $5,290 | ||
Rank 5; likely between #3 and #8 of 78Blood Cancer DiscoveryAmerican Association for Cancer Research · United States | 2.27Q1 | 8.28 1.23 up from 2024 | 116 | 76% | — | ||
Rank 6; likely between #3 and #7 of 78Blood ReviewsElsevier BV · United Kingdom | 2.23Q1 | 7.59 1.51 up from 2024 | 180 | 51% | $5,220 | ||
Rank 7; likely between #5 and #9 of 78American Journal of HematologyWiley · United States | 2.01Q1 | 6.12 0.56 up from 2024 | 1,024 | 79% | $5,450 | ||
Rank 8; likely between #7 and #9 of 78Blood AdvancesOAElsevier BV · United States | 1.89Q1 | 5.87 0.09 up from 2024 | 2,061 | 100% | $3,800 | Falling vs field, 2022–25 | |
Rank 9; likely between #9 and #12 of 78HematologyAmerican Society of Hematology · United States | 1.56Q1 | 4.14 0.30 up from 2024 | 294 | 100% | — | Rising vs field, 2022–25 | |
Rank 10; likely between #9 and #12 of 78Journal of Thrombosis and HaemostasisElsevier BV · United Kingdom | 1.54Q1 | 4.52 0.34 up from 2024 | 1,103 | 67% | $3,750 | Falling vs field, 2022–25 | |
Rank 11; likely between #7 and #18 of 78Seminars in HematologyElsevier BV · United States | 1.48Q1 | 4.34 0.02 up from 2024 | 132 | 31% | $4,070 | ||
Rank 12; likely between #7 and #28 of 78Current Hematologic Malignancy ReportsSpringer Science+Business Media · United States | 1.34Q1 | 4.36 0.55 up from 2024 | 87 | 45% | $3,790 | ||
Rank 13; likely between #10 and #17 of 78HemaSphereOAWolters Kluwer · United States | 1.32Q1 | 3.90 0.13 up from 2024 | 448 | 100% | $2,480 | Rising vs field, 2022–25 | |
Rank 14; likely between #12 and #18 of 78Transplantation and Cellular TherapyElsevier BV · Netherlands | 1.23Q1 | 3.97 0.46 down from 2024 | 913 | 89% | $3,650 | Rising vs field, 2022–25 | |
Rank 15; likely between #12 and #17 of 78HaematologicaOAFerrata Storti Foundation · Italy | 1.22Q1 | 3.44 0.21 down from 2024 | 1,235 | 100% | $2,157 | Falling vs field, 2022–25 | |
Rank 16; likely between #11 and #28 of 78Best Practice & Research Clinical HaematologyElsevier BV · United Kingdom | 1.14Q1 | 3.45 1.05 up from 2024 | 119 | 35% | $3,730 | ||
Rank 17; likely between #14 and #26 of 78PlateletsOAInforma · United Kingdom | 1.07Q1 | 3.31 0.67 up from 2024 | 216 | 100% | $2,970 | ||
Rank 18; likely between #14 and #28 of 78Current Opinion in HematologyLippincott Williams & Wilkins · United States | 1.06Q1 | 3.65 0.75 up from 2024 | 116 | 33% | — | ||
Rank 19; likely between #14 and #28 of 78Therapeutic Advances in HematologyOASAGE Publishing · United Kingdom | 1.05Q1 | 2.90 0.75 down from 2024 | 173 | 100% | $2,650 | ||
Rank 20; likely between #15 and #25 of 78Bone Marrow TransplantationSpringer Nature · United Kingdom | 1.04Q1 | 3.20 0.10 up from 2024 | 852 | 45% | $4,990 | ||
Rank 21; likely between #16 and #25 of 78Research and Practice in Thrombosis and HaemostasisOAElsevier BV · United States | 1.03Q2 | 2.94 0.06 up from 2024 | 845 | 100% | $2,250 | ||
Rank 22; likely between #14 and #33 of 78Journal of Blood MedicineOADove Medical Press · New Zealand | 0.99Q2 | 2.43 1.10 down from 2024 | 194 | 100% | $2,320 | ||
Rank 23; likely between #17 and #31 of 78Seminars in Thrombosis and HemostasisThieme Medical Publishers (Germany) · United States | 0.97Q2 | 3.26 0.31 down from 2024 | 354 | 19% | — | ||
Rank 24; likely between #22 and #30 of 78British Journal of HaematologyWiley · United Kingdom | 0.92Q2 | 2.75 0.09 up from 2024 | 1,736 | 70% | $5,190 | Falling vs field, 2022–25 | |
Rank 25; likely between #16 and #36 of 78Blood ResearchOASouth Korea | 0.91Q2 | 2.66 0.31 up from 2024 | 178 | 100% | $2,290 | Rising vs field, 2022–25 | |
Rank 26; likely between #15 and #38 of 78Transfusion Medicine ReviewsElsevier BV · United States | 0.91Q2 | 3.35 0.84 up from 2024 | 79 | 41% | $3,970 | ||
Rank 27; likely between #22 and #31 of 78Pediatric RheumatologyOABioMed Central · United Kingdom | 0.89Q2 | 2.39 0.24 down from 2024 | 364 | 100% | $3,090 | Falling vs field, 2022–25 | |
Rank 28; likely between #21 and #33 of 78European Journal Of HaematologyWiley · United Kingdom | 0.89Q2 | 2.74 0.33 up from 2024 | 581 | 72% | $4,650 | ||
Rank 29; likely between #21 and #36 of 78Annals of Laboratory MedicineOASeoul National University · South Korea | 0.86Q2 | 2.88 0.45 up from 2024 | 270 | 100% | — | ||
Rank 30; likely between #23 and #37 of 78Expert Review of HematologyTaylor & Francis · United Kingdom | 0.82Q2 | 2.77 0.38 up from 2024 | 303 | 33% | — | ||
Rank 31; likely between #20 and #43 of 78Clinical Hematology InternationalOASpringer Nature · Netherlands | 0.82Q2 | 2.26 0.36 up from 2024 | 91 | 100% | — | ||
Rank 32; likely between #28 and #37 of 78HaemophiliaWiley · United Kingdom | 0.77Q2 | 2.57 0.14 up from 2024 | 595 | 67% | $4,760 | ||
Rank 33; likely between #24 and #43 of 78Current Research in Translational MedicineElsevier BV · France | 0.76Q2 | 2.27 0.16 up from 2024 | 117 | 30% | $3,700 | ||
Rank 34; likely between #11 and #60 of 78Journal of Clinical ApheresisWiley · United States | 0.76Q2 | 2.90 0.02 up from 2024 | 175 | 52% | $3,920 | ||
Rank 35; likely between #19 and #51 of 78Blood ScienceOAWolters Kluwer · United States | 0.73Q2 | 2.54 0.25 up from 2024 | 113 | 100% | — | ||
Rank 36; likely between #31 and #45 of 78Experimental HematologyElsevier BV · United States | 0.69Q2 | 2.59 0.55 up from 2024 | 227 | 17% | $3,250 | ||
Rank 37; likely between #29 and #47 of 78Transfusion Medicine and HemotherapyOAKarger Publishers · Switzerland | 0.69Q2 | 2.15 0.10 up from 2024 | 158 | 100% | $1,670 | ||
Rank 38; likely between #33 and #45 of 78Leukemia ResearchElsevier BV · United Kingdom | 0.67Q2 | 2.02 0.21 up from 2024 | 350 | 20% | $3,910 | ||
Rank 39; likely between #35 and #44 of 78Annals of HematologyOASpringer Science+Business Media · Germany | 0.66Q2 | 2.06 0.05 up from 2024 | 1,373 | 100% | $4,590 | Falling vs field, 2022–25 | |
Rank 40; likely between #31 and #49 of 78Cytometry Part B Clinical CytometryWiley · United States | 0.65Q3 | 2.77 0.69 up from 2024 | 144 | 52% | $3,800 | ||
Rank 41; likely between #34 and #46 of 78International Journal of HematologySpringer Science+Business Media · Japan | 0.65Q3 | 1.90 0.11 down from 2024 | 607 | 35% | $4,390 | ||
Rank 42; likely between #34 and #46 of 78HematologyOAManey Publishing · United Kingdom | 0.64Q3 | 2.09 0.39 up from 2024 | 507 | 100% | $2,557 | ||
Rank 43; likely between #35 and #46 of 78Clinical Lymphoma Myeloma & LeukemiaElsevier BV · United States | 0.64Q3 | 1.95 0.21 up from 2024 | 653 | 5% | $3,890 | ||
Rank 44; likely between #30 and #52 of 78HämostaseologieThieme Medical Publishers (Germany) · Germany | 0.63Q3 | 1.08 0.26 down from 2024 | 275 | 24% | — | ||
Rank 45; likely between #31 and #53 of 78Hematology ReportsOAPAGEPress (Italy) | 0.61Q3 | 2.17 0.60 up from 2024 | 199 | 100% | $1,930 | ||
Rank 46; likely between #29 and #57 of 78Acta HaematologicaKarger Publishers · Switzerland | 0.58Q3 | 1.67 0.12 up from 2024 | 181 | 52% | — | ||
Rank 47; likely between #43 and #51 of 78TransfusionWiley · United States | 0.55Q3 | 1.90 0.10 up from 2024 | 1,034 | 63% | $4,100 | Falling vs field, 2022–25 | |
Rank 48; likely between #44 and #52 of 78Leukemia & lymphoma/Leukemia and lymphomaTaylor & Francis · Switzerland | 0.53Q3 | 1.61 0.02 up from 2024 | 998 | 21% | — | ||
Rank 49; likely between #43 and #55 of 78International Journal of Laboratory HematologyWiley · United Kingdom | 0.52Q3 | 1.72 0.19 up from 2024 | 587 | 47% | $3,880 | ||
Rank 50; likely between #36 and #60 of 78Frontiers in HematologyOAFrontiers Media | 0.51Q3 | 1.71 0.77 up from 2024 | 103 | 100% | $2,353 |
5 Hematology journals are labelled rising: their OJR moved up between 2022 and 2025 clearly faster than the median journal of their field or domain.
A journal is rising when its OJR grew from 2022 to 2025 faster than the median journal of its field (or domain, when the field is small), by two tests: the relative change is +10% or more, and it is at least 2 standard errors above zero. So the range of the change at 2 standard errors stays above zero, though not necessarily above +10%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the low end of the range, so the surest rises come first.
- 1Blood ResearchOASouth Korea+89% vs groupOJR 0.52 → 0.91range +36% to +163%
- 2HemaSphereOAWolters Kluwer · United States+65% vs groupOJR 0.85 → 1.32range +30% to +110%
- 3eJHaemOAWiley · United States+56% vs groupOJR 0.28 → 0.41range +19% to +104%
- 4HematologyAmerican Society of Hematology · United States+35% vs groupOJR 1.24 → 1.56range +12% to +63%
- 5Transplantation and Cellular TherapyElsevier BV · Netherlands+26% vs groupOJR 1.04 → 1.23range +7.8% to +47%
No-label zone, -9.1% to +10%Group median changeBar scale -64% to +175% (ratio scale)
10 Hematology journals are labelled falling: their OJR moved between 2022 and 2025 clearly behind the median journal of their field or domain.
A journal is falling when its OJR changed from 2022 to 2025 by less than the median journal of its field (or domain, when the field is small), by two tests: the relative change is -9.1% or less (rounded), and it is at least 2 standard errors below zero. So the range of the change at 2 standard errors stays below zero, though not necessarily below -9.1%.
The bar is that range on a ratio scale; the shaded band, -9.1% to +10%, holds changes too small for a label. The list is ordered by the high end of the range, so the surest falls come first.
- 1Journal of Thrombosis and HaemostasisElsevier BV · United Kingdom-38% vs groupOJR 2.67 → 1.54range -53% to -20%
- 2Vox SanguinisWiley · United Kingdom-34% vs groupOJR 0.77 → 0.48range -48% to -17%
- 3HaematologicaOAFerrata Storti Foundation · Italy-19% vs groupOJR 1.61 → 1.22range -28% to -8.9%
- 4British Journal of HaematologyWiley · United Kingdom-14% vs groupOJR 1.13 → 0.92range -22% to -4.6%
- 5Transfusion and Apheresis ScienceElsevier BV · United Kingdom-22% vs groupOJR 0.50 → 0.37range -36% to -4.5%
- 6TransfusionWiley · United States-16% vs groupOJR 0.69 → 0.55range -26% to -4.1%
- 7Mediterranean Journal of Hematology and Infectious DiseasesOAPAGEPress (Italy) · Italy-27% vs groupOJR 0.71 → 0.49range -45% to -3.9%
- 8Pediatric RheumatologyOABioMed Central · United Kingdom-19% vs groupOJR 1.17 → 0.89range -31% to -3.5%
- 9Blood AdvancesOAElsevier BV · United States-12% vs groupOJR 2.29 → 1.89range -20% to -3.1%
- 10Annals of HematologyOASpringer Science+Business Media · Germany-16% vs groupOJR 0.84 → 0.66range -28% to -1.2%
No-label zone, -9.1% to +10%Group median changeBar scale -54% to +119% (ratio scale)
Subfields of Medicine, with Hematology highlighted.
- Surgery945
- Pulmonary and Respiratory Medicine352
- Public Health, Environmental and Occupational Health311
- Cardiology and Cardiovascular Medicine287
- Infectious Diseases258
- Oncology242
- Epidemiology178
- Neurology168
- Radiology, Nuclear Medicine and Imaging160
- Physiology154
- Endocrinology, Diabetes and Metabolism152
- Psychiatry and Mental health139
- Orthopedics and Sports Medicine121
- Ophthalmology96
- Pediatrics, Perinatology and Child Health95
- Dermatology89
- Obstetrics and Gynecology81
- Hematology78
- Rheumatology70
- Nephrology62
- Complementary and alternative medicine58
- Reproductive Medicine53
- Pharmacology49
- Emergency Medicine44
- Geriatrics and Gerontology38
- Otorhinolaryngology32
- Rehabilitation31
- Pathology and Forensic Medicine29
- Hepatology28
- Immunology and Allergy25
- Critical Care and Intensive Care Medicine24
- Genetics19
- Anesthesiology and Pain Medicine14
- Urology13
- Health Informatics10
- Gastroenterology6
- Internal Medicine6
- Family Practice2
- Transplantation2
- Anatomy0
- Biochemistry0
- Microbiology0
Journals
The endpoints below each rank show its likely range. How rank ranges are calculated
Citations made in 2025. Corpus-wide, 84.3% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
9 additional Hematology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2022–2024, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2025. Publication window: 2022–2024. How these summaries are calculated
- Ranked journals
- 78
- Window papers (baseline)
- 47,302 +2.9% from indicator year 2022
- Median OJR
- 0.658 -3.6% from indicator year 2022
- Rising journals (2025)
- 5
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2022–2024 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 37 | 43 | 47 | 48 | 49 | 48 | 48 | 51 | 52 | 55 | 57 | 59 | 60 | 64 | 69 | 71 | 70 | 74 | 78 | 80 | 79 | 83 | 83 | 84 | 83 | 78 | |
| Window papers (baseline) | 15,676 | 17,554 | 18,321 | 19,931 | 20,773 | 22,160 | 23,086 | 23,968 | 25,638 | 27,756 | 31,370 | 32,535 | 33,270 | 32,125 | 33,484 | 34,476 | 35,772 | 36,578 | 37,717 | 39,004 | 40,629 | 43,037 | 45,948 | 47,337 | 47,502 | 47,302 | |
| Median OJR | 0.53 | 0.57 | 0.589 | 0.593 | 0.641 | 0.646 | 0.677 | 0.650 | 0.640 | 0.663 | 0.62 | 0.73 | 0.707 | 0.713 | 0.7205 | 0.716 | 0.7196 | 0.75 | 0.74 | 0.68294 | 0.711 | 0.682 | 0.68287 | 0.63 | 0.587 | 0.658 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.